Harnessing beneficial bacteria to treat chronic inflammatory skin conditions.
La Jolla, San Diego
Joined June 2017
- Tweets51
- Following41
- Followers69
- Likes2
MatriSys announces positive results from a study of S. felis for the treatment of drug-resistant S. pseudintermedius. bit.ly/3aTYwlZ bit.ly/3DYNU1u #dermatology #skinmicrobiome
Dr. Philippe Calais, CEO of @MatriSysBio, will be presenting at the @MicrobiomeDaily 4th Microbiome Movement – Skin Health & Dermatology Summit (microbiome-dermatology.com/) on August 4th at 4:15 p.m. ET. bit.ly/2VdKjLY
We are pleased to announce that Dr. Joyce Rico is joining MatriSys as Chief Medical Officer. Dr. Rico’s 20 years of experience in early and late-stage #dermatology drug development, product launch, and drug safety is a welcome addition to our team.
MatriSys Bioscience licenses compound for harnessing beneficial bacteria to treat #acne, building upon company pipeline targeting inflammatory skin diseases. bit.ly/3rZ2ro9 #dermatology #skinmicrobiome
MatriSys Bioscience raises more than $3 million to advance its platform developing #skinmicrobiome therapies for inflammatory skin diseases. #dermatology
Published @NatureMedicine study on @MatriSysBio’s lead compound for #atopicdermatitis reveals the potential of beneficial bacteria to treat chronic skin diseases. bit.ly/3qOt92g #dermatology #microbiome
Important new science from the NIH - How genetic variations cause eczema nih.gov/news-events/news-rel…
MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics is pleased to announce that it was named a 2020 “Cool Company” by Connect/San Diego Venture Group (SDVG). bit.ly/2XakFpR
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors bit.ly/2XzHlyX
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors bit.ly/3bQucXv
